Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
12:03am, Wednesday, 03'rd Jun 2026
Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's disease while preservi
Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification
06:24pm, Tuesday, 02'nd Jun 2026
CNBC's Jim Cramer said investors should consider adding exposure to out-of-favor sectors if investors begin rotating away from high-flying technology stocks. He highlighted JPMorgan, Johnson & Johnson
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic
02:30pm, Tuesday, 02'nd Jun 2026
AbbVie's shareholders can sleep easy.
No Rate Cuts Until 2027? Grab These High-Yielding Safe Dividend Kings Now
08:20am, Monday, 01'st Jun 2026
Persistent inflation is likely to keep the Federal Reserve from cutting rates until well into 2027.
How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier
01:41pm, Sunday, 31'st May 2026
The income target is straightforward: $12,500 a month equals $150,000 a year, and the portfolio doing the work is $2.8 million. Dividing the income by the capital gives the math the whole article has
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where
Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris
More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not yet reached, as reported in new Journal of Clinical Oncology publica
Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death Data selected to open the
J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study
08:01am, Sunday, 31'st May 2026
Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the ri
The Two Bucket Income Portfolio That Pays $5,000 a Month Plus a Cash Reserve to Survive 2008 Style Drawdowns
09:18am, Saturday, 30'th May 2026
Generating $5,000 per month in passive income works out to $60,000 annually, a level many retirees target to cover core expenses without relying heavily on Social Security or selling assets during mar
How to Recession-Proof Your Retirement Income Before Summer 2026
09:15am, Saturday, 30'th May 2026
High energy prices have investors worried about a recession; these businesses should survive the hit just fine.
Johnson & Johnson (JNJ) Shares Fall 2.4% -- What GF Score of 87 Tells Investors
09:29pm, Friday, 29'th May 2026
On May 29, 2026, Johnson and Johnson (JNJ) shares fell 2.4% to a current price of $225.33. Over the past 52 weeks, the stock has traded between a low of $149.04 a
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
06:46pm, Friday, 29'th May 2026
Johnson & Johnson (JNJ) reached $225.33 at the closing of the latest trading day, reflecting a -2.37% change compared to its last close.
Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent responses observed across atypi
